Biomarker-Driven Lung Cancer Care: Application of New Standards and the Latest Research

Deepen your understanding of the role of biomarkers in lung cancer treatment and learn how to apply recent biomarker data from key clinical trials in a webcast from a live symposium with associated downloadable slides and an expert commentary.

Share

Program Content

Activities

NSCLC: Molecular Testing
The Importance of Molecular Testing in NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

NSCLC: <i>EGFR</i>, <i>KRAS</i>, and <i>HER2</i>
Treatment Options for the Common Targetable Biomarkers for Advanced NSCLC: EGFR, KRAS, and HER2
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

Less Common Driver Mutations in NSCLC
Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: MET, RET, ALK, ROS, NTRK
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

No activities added yet

Activities

Advanced NSCLC: Biomarker Testing
2 Patients From My Practice Who Illustrate the Importance of Biomarker Testing For Advanced NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2022

Expires: September 22, 2023

Faculty

cover img faculity

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

cover img faculity

Narjust Florez, MD

Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor, JAMA Oncology
Boston, Massachusetts

cover img faculity

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc